Member Info for Bigears1170

An absolute catastrophe of a CEO !

If there is a raise at anything like these levels Coughlin should be fired !

I see the sp doing it’s obligatory dive following a Coughlin public speaking engagement

Harry is a w@nk3r and a trouble maker , a bitter cuckoo in the nest.....he will be snipping from the side lines for the rest of his days

Retail interest is the only thing that will drive the SP short term and they ain’t interested with our CLN sucking the life out of the SP - Tapp & Co may as well be speaking in Swahili and the posters written in hieroglyphics as they mean nothing to the average Joe Public - large biotech also not interested at five year lows and GSA sticking to their short like shat to a blanket…….. remove / deal with the CLN / funding as promised 12 months ago and all of the afore mentioned changes in the blink of an eye - PS the markets gravitate to companies / CEO’s that stay true to their word ……….🫤

Judging by the responses and the sea of green boxes, I see the narcissistic “ the science is great, ignore everything else brigade ” are out in force.

I would urge the 34 who have liked the letter to print it off and send it in , the holding of those 34 to include my holding will be significant and worthy of note to the bod.

100% I will , everyone who agrees with it should send it

I urge the board to address these issues with transparency and urgency. Specifically, I request:

- A detailed update on financing plans ( as promised 30th April 2024 ) and CLN resolution strategy within the next 30 days.

- A clear plan to strengthen the board with commercially experienced leaders, including a timeline for recruitment.

In conclusion, shareholders hold the work of our scientists and Scientific Advisory Board in the highest regard but remain concerned that the board, in its current composition, may not be optimally positioned to drive the company’s commercial success. I urge the board to address these concerns with urgency and look forward to your prompt response and tangible progress on these matters.

Yours Sincerely

CC - Mr Shaun Chilton

If in agreement with this letter print & post to CEO, tweet & retweet on X

Dr Christina Coughlin

Chief Exective Officer

Avacta Group PLC

Scale Space

White City

Imperial College Campus

58 Wood Lane

London

W12 7RZ

Dear Dr. Coughlin,

I am writing to express my concern regarding the lack of commercial progress over the past 12 months.

Following the Investor Meeting and Q&A on April 30, 2024, you outlined four key priorities for the board, which I wish to address.

1. Pipeline - Shareholders have unwavering confidence in our scientists and Scientific Advisory Board. Their expertise and dedication are highly valued, and their contributions remain a cornerstone of the business.

2. Financing - You stated during the Q&A that the board was actively pursuing funding to support innovation, with “everything on the table” and a commitment to provide a prompt update. Regrettably, no such update has been forthcoming. Shareholders urgently seek clarity on the board’s strategy to secure financing and the timeline for communicating progress.

3. Diagnostics - Shareholders widely commend the board for successfully completing the sale of the diagnostics division, a positive milestone for the company.

4. Board Composition - There is a widely held view among shareholders that the board lacks sufficient commercial expertise. Investors expect leadership with proven industry experience, deep market knowledge, and a clear vision to navigate the complexities of our sector effectively.

Additionally, I wish to address the Convertible Loan Note (CLN), which has been a significant concern for shareholders over the past year. Approved by four of the seven current board members, this instrument’s quarterly repayments and subsequent share issuances have severely undermined market sentiment, contributing to a five-year low in the company’s stock price as of this writing. The board’s failure to anticipate this impact raises serious questions about its commercial judgment, reinforcing concerns about its composition. Moreover, there is a consensus among shareholders that the board has not provided a credible explanation for its inability to resolve this issue.

During the Q&A, you acknowledged shareholder concerns, stating, “We hear your concerns.” However, the board’s actions appear inconsistent with prior commitments. For instance, in April 2024, you emphasised that funding innovation was a “key priority” and promised answers “in a short bit of time.” Yet, nearly a year later, the board has attributed challenges to the commercial environment while proceeding with stock conversions, despite previously signaling that the diagnostics division disposal were factors in historic decisions. This disconnect has led shareholders to question whether the board possesses the necessary skill set to lead effectively.

So something of a quandary that whilst global air travel has increased 37% since 2014, WSGs share price has depreciated 98% in the same period 🤭 …. How does that compute ?

Touk

Where did I say I wanted Coughlin to “ make things up “ ?

I am well aware of her timelines, in the absence of any commercial savvy to give the SP a kick she has firmly hung her hat on our scientists.

She has nearly four years worth of positive in - clinic data in her handbag, yet she is incapable of selling it , she doesn’t possess the skillset.

My beef is financing and the bods inability to deal with the CLN.

A CEO with stock market instincts and commercial savvy would have stemmed or removed the bleed of the CLN given a 12 month window , that she hasn’t found a home for any of it is in my opinion a gross dereliction of duty, she possesses zero CEO polish.

PS - Financing was a short term key priority 11 months ago …..🫤

If you were to sit in your dentist's chair for a root canal procedure only to be told that the dentist had been fired the day before, and that you would have to make do with the anesthetist on the other end of the drill, would it not give you cause for concern?

That is exactly what we have here , an Oncologist playing at being a CEO, which is demonstrably reflected in that share price. Yet, Coughlin gets a pass because the scientists are knocking the ball out of the park.

I would sack her in the blink of an eye….. I would also add that this company will be a success in spite of her and not because of her ……

Yep , it’s all Trumps fault 🤣 , the SP has been nose diving since September and our excuse of a CEO has done sweet FA to prevent it

Sub £100 Mcap inbound- Coughlin needs replacing , she isn't fit for purpose

She got the job for no other reason than she wasn’t AS - to call her a commercial halfwit is putting it mildly , and on company performance over the last 10 months Chilton isn’t too far behind her.

The thing that exasperates me is that she clearly did not have the credentials for the CEO job, and her Oncology expertise was already in the company so what was it that she added to the business by giving her the CEO hat ?

It’s a tricky one as our leadership team are yet to exhibit any of their alleged commercial wizardry !

They inexplicably thought it a bright idea to pay in cash when the SP resided at 68p , that day there was a circa 15% intraday high.

We are arguably in a better financial situation today than last July, if there is any substance to the talk of impending licence deals its a no brainier that the CLN will / should be a cash payment .

The fact that the sp sits circa 60% down on that day only reinforces the idea ( at least in my world).

It’s like Mr Benn on this BB. I see the oncologist & science outfits have been left in the wardrobe & out come the trade economist costumes 😂

“Can’t wait to see you all scramble and pretend you held. Soon”

Not a chance in hell…!

Meanwhile GSA stick with their short like $h**e to a blanket …. Truly bizarre that they appear to see no jeopardy in it 🧐

So is it a given that the fast track approval (FTA) process is running concurrent with the trial or would a FTA review commence once PFS has been established ?